BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Abp 234 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Abp 234\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06430866-2085@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Abp 234: Phase 3 readout est. (NCT06430866)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pharmac
 okinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)\nEstima
 ted primary completion: 14 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abp-234#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06430866
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-2085@assetmemo.bio
DTSTAMP:20261121T005625Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Abp 234: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Ad
 vanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abp-234#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
